SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 52.51+2.7%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (5581)2/1/2002 3:44:40 PM
From: Mike McFarland  Read Replies (1) of 52153
 
A month ago you posted an article on Biotech IPOs

Among the Bay Area's losers, Exelixis closed 28 percent below its IPO opening on Friday. Durect, Genencor, Sangamo BioSciences and Rigel Pharmaceuticals were off between 35 and 45 percent. Kosan Biosciences, Deltagen and Cepheid are worth about half of what investors paid for them initially.

Shares in Maxygen and Virologic are roughly 60 percent below what they commanded at their IPO opening. Ciphergen Biosystems, Large Scale Biology and Aclara BioSciences are off more like 80 percent.

And today Zymogenetics, ZGEN, came out priced well below
where they had intended.

Whew, I cannot keep track of them all.
But there must be a few keepers in the list;
are there any you are watching with great interest
Wilder and everybody else?

quote.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News